MatthewDSimsMDPhD, FACP, FIDSA

Director of Infectious Diseases Research, Beaumont Health. Professor, Internal Medicine and Biomedical Sciences, Oakland University William Beaumont School of Medicine

Join to view full profile

Dr. Sims is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sims' full profile

Already have an account?

Office
3535 W. 13 Mile Rd
Suite 605
Royal Oak, MI 48073
Phone+1 248-551-0495

Fax+1 248-551-7268

Education & Training

University of RochesterFellowship, Infectious Disease, 2003 - 2006
Stony Brook Medicine/University HospitalResidency, Internal Medicine, 2000 - 2003
Stony Brook University Health Sciences Center School of MedicineClass of 2000

Certifications & Licensure

MI State Medical License 2006 - 2025
NY State Medical License 2003 - 2006
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME) Start of enrollment: 2012 Oct 06
Completed
Phase 3
Study of Debio 1450 for Bacterial Skin Infections Start of enrollment: 2015 May 01
Completed
Phase 2
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) Start of enrollment: 2015 May 01
Completed
Phase 2
Screening to Prophylax Against Clostridium Difficile Infection - Start of enrollment: 2016 Dec 01
Completed
Phase 4
Beaumont Health Large-scale Automated Serologic Testing for COVID-19 Start of enrollment: 2020 Apr 10
Completed
Treatment of Pneumocystis in COPD (the TOPIC Study) Start of enrollment: 2022 Sep 28
Terminated
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

24 citations
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with RecurrentInfection (rCDI).
Sahil Khanna, Matthew Sims, Thomas J Louie, Monika Fischer, Kerry LaPlante
Antibiotics. 2022-09-10
9 citations
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
Charles S Berenson, Bret Lashner, Louis Y Korman, Elizabeth Hohmann, Abhishek Deshpande
Clinical Infectious Diseases. 2023-11-30
105 citations
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone i...
Matthew Sims, Valeri Mariyanovski, Patrick McLeroth, Wayne Akers, Yu-Chieh Lee
The Journal of Antimicrobial Chemotherapy. 2017-09-01

Journal Articles

Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia
Issam Raad, Mark E Rupp, Thomas L Holland, Helen W Boucher, G Ralph Corey, Paul Riska, Deverick J Anderson, Matthew Sims, Dannah Wray, Sara E Cosgrove, Manuela Carugat..., JAMA

Press Mentions

How Wayne State Grad and St. Clair Shores Native Helped Create New RSV VaccineMay 5th, 2023
Masks Few and Far Between Three Years After COVID-19 Pandemic BeganApril 27th, 2023
Coronavirus Tracker | Cases Fall; Fewest Hospitalizations in Nearly Two YearsApril 26th, 2023
Join now to see all